Protox Therapeutics

Contact
protoxtherapeutics.com
+16046880199

Protox Therapeutics Inc.

1210-885 West Georgia Street
V6C 3E8 Vancouver
Canada
+16046880199
protoxtherapeutics.com
Contact
Profile Products News
Contact

About Protox Therapeutics

Protox Therapeutics is a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases. Two novel drug candidates derived from the company's INxin(TM) and PORxin(TM) platforms are being developed in three clinical programs. A Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary brain cancer has been completed and the drug has received Fast Track Designation and Orphan Drug Status from the US FDA. Phase 1 clinical trials evaluating PRX302 (PORxin) have been completed for the treatment of localized prostate cancer and benign prostatic hyperplasia (enlarged prostate).

Read more about Protox Therapeutics
Facts about Protox Therapeutics
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Protox Therapeutics

Product portfolio

Show all

News about Protox Therapeutics

Protox Therapeutics

13-Jan-2010 | research and development

Protox announces positive Phase 2b BPH results

Protox Therapeutics Inc. announced positive top-line results from its double-blinded placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in ...

Read news
Protox Therapeutics

10-Sep-2009 | research and development

Protox completes enrollment of Phase 2b BPH trial

Protox Therapeutics Inc. announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of ...

Read news
Protox Therapeutics

19-May-2008 | research and development

Protox doses first patient in Phase 2 BPH clinical trial

Protox Therapeutics Inc. announced the enrolment and successful dosing of the first patient in a Phase 2 clinical trial evaluating PRX302 to treat benign ...

Read news
Protox Therapeutics

21-Apr-2008 | research and development

Protox announces positive long-term data from BPH study

Protox Therapeutics Inc. announced positive results from its Phase 1 study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH), a common ...

Read news
Protox Therapeutics

07-Jan-2008 | research and development

Protox announces positive final results from BPH study

Protox(TM) Therapeutics Inc. announced positive final results from its Phase 1 study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH ...

Read news
Protox Therapeutics

23-Aug-2007 | business & finance

Protox acquires research program from Medicenna

Protox Therapeutics Inc. announced that it has entered into an asset purchase agreement with Medicenna Ventures Inc. for the acquisition of Medicenna's ...

Read news
Protox Therapeutics

15-Dec-2005 | research and development

Protox files foundation patent for PORxin(TM) technology

Protox Therapeutics Inc. announced that it has filed a provisional patent application with the United States Patent and Trademark Office entitled "Modified ...

Read news
Protox Therapeutics

11-Aug-2005 | research and development

Protox signs exclusive Lung Cancer licence agreement and initiates Lung Cancer study

Protox Therapeutics Inc. announced that it has signed an exclusive licence agreement with the National Research Council Institute for Biological Sciences ( ...

Read news
Show more news about Protox Therapeutics

Here you will find Protox Therapeutics Inc.